Hovione Partners with Ripple Therapeutics to Expand Epidel® Platform
Tuesday, March 21, 2023
Hovione and Ripple Therapeutics have entered a strategic partnership to expand the use of Ripple's Epidel® platform beyond ophthalmic applications.
The goal of this partnership is to accelerate and expand the availability of this highly innovative and enabling technology for the benefit of the pharmaceutical customers and their patients worldwide. Expanding the use of the Epidel® platform beyond ophthalmic applications, this partnership enables a diverse portfolio of new products with an optimal sustained release profile.
The core feature of Ripple’s Epidel® technology is the ability to deliver sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. This enables higher drug loading, smaller size implants, defined and predictable biocompatible degradation products with straightforward and scalable manufacturing processes. Surface erosion-based drug release provides a highly effective way to control dose and duration. By incorporating Ripple's Epidel® platform into its toolbox, Hovione can expand its portfolio of novel drug delivery solutions to the pharmaceutical industry.
